Table 2 NAPSI, f-PGA, PASI, and DLQI through week 48 by treatment subgroup

Guselkumab response continuation

Treatment received

Guselkumab

Re-randomized to guselkumab at week 28

NAPSI

4.4 (1.8)

2.4 (2.2)

1.8 (2.0)

1.2 (1.6)

 Nail matrix

2.5 (1.2)^a

1.4 (1.3)

1.0 (1.2)

0.7 (1.0)

 Nail bed

1.9 (1.2)

1.0 (1.1)

0.8 (1.0)

0.5 (0.8)

 n

108

106

107

105

f-PGA

2.4 (0.9)

1.1 (0.9)

0.9 (0.9)

0.7 (0.8)

 n

108

106

107

105

PASI

22.6 (8.8)

1.2 (2.1)

0.6 (1.1)

1.3 (3.5)

 n

108

108

108

106

DLQI

14.3 (6.4)

2.9 (4.2)

2.3 (4.0)

1.8 (3.4)

 n

107

108

108

104

Guselkumab non-response continuation

Treatment received

Guselkumab

Guselkumab continuation at week 28

NAPSI

4.9 (2.0)

3.6 (2.2)

2.9 (2.4)

1.9 (2.0)

 Nail matrix

2.7 (1.2)

2.1 (1.4)

1.6 (1.4)

1.0 (1.2)

 Nail bed

2.1 (1.3)

1.5 (1.3)

1.3 (1.3)

0.9 (1.0)

 n

61

61

60

56

f-PGA

2.7 (0.9)

1.7 (0.8)

1.5 (1.0)

1.1 (1.0)

 n

61

61

60

56

PASI

23.1 (9.8)

5.6 (5.4)

5.2 (5.1)

5.5 (9.4)

 n

63

63

62

58

DLQI

16.0 (8.0)

5.7 (6.2)

5.0 (5.4)

4.8 (5.7)

 n

63

63

62

58

Guselkumab response withdrawal^b

Treatment received

Guselkumab

Re-randomized to placebo at week 28

NAPSI

5.0 (2.1)

2.5 (1.9)

1.7 (1.9)

1.9 (2.1)

 Nail matrix

2.7 (1.3)

1.5 (1.3)

1.0 (1.2)

0.9 (1.3)

Nail bed

2.2 (1.2)

0.9 (1.0)

0.7 (1.0)

1.0 (1.1)

 n

97

96

96

96

f-PGA

2.5 (0.8)

1.3 (0.9)

0.9 (0.8)

1.1 (1.0)

 n

98

97

97

97

PASI

23.1 (9.0)

1.3 (2.7)

0.6 (1.4)

5.2 (6.1)

 n

101

101

100

100

DLQI

14.5 (6.1)

2.8 (4.1)

2.2 (3.6)

7.0 (7.4)

 n

101

101

100

100

Adalimumab withdrawal^c

Treatment received

Adalimumab

Switch to placebo at week 28

NAPSI

4.7 (1.9)

2.0 (2.2)

1.4 (1.6)

2.3 (2.4)

 Nail matrix

2.6 (1.2)

1.2 (1.2)

1.0 (1.3)

1.2 (1.2)

 Nail bed

2.1 (1.1)

0.8 (1.1)

0.4 (0.7)

1.1 (1.3)

 n

62

61

61

61

f-PGA

2.6 (0.8)

1.0 (1.0)

0.7 (0.8)

1.5 (1.2)

 n

62

61

61

61

PASI

22.7 (8.6)

1.6 (2.6)

0.6 (0.8)

7.4 (6.0)

 n

65

65

65

64

DLQI

15.2 (6.1)

2.4 (3.2)

1.8 (2.9)

8.7 (7.4)

 n

64

65

65

63

Adalimumab to guselkumab

Treatment received

Adalimumab

Switch to guselkumab at week 28

NAPSI

4.2 (1.9)

2.3 (2.1)

2.2 (2.1)

1.5 (1.9)

 Nail matrix

2.2 (1.4)

1.2 (1.3)

1.2 (1.4)

0.9 (1.2)^{a d}

 Nail bed

2.0 (1.0)

1.1 (1.1)

1.0 (1.1)

0.7 (1.0)^{a d}

 n

66

65

65

63

f-PGA

2.4 (0.8)

1.3 (1.0)

1.2 (1.0)

0.9 (0.9)

 n

65

66

65

64

PASI

20.1 (8.5)

6.8 (7.3)

7.1 (8.2)

1.8 (2.5)

 n

67

67

67

66

DLQI

15.3 (8.0)

7.6 (7.6)

8.0 (8.3)

2.9 (3.7)

 n

67

67

67

65